Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion type Assertion NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_head.
- NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_provenance.
- NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion evidence source_evidence_literature NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_provenance.
- NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion SIO_000772 22895556 NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_provenance.
- NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion wasDerivedFrom befree-20150227 NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_provenance.
- NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_assertion wasGeneratedBy ECO_0000203 NP978725.RAgGAP4-5v-Z5LXuOZAXWbOwaqZW_dT2_OxZSZQCbKVV4130_provenance.